Jake Van Naarden

President of Oncology and Head of Business Development, Eli Lilly

· tracked since Jun 2026

Calls 1 1 Posts tracked · 1.0/day Posted today

Calls

7d 1

30d 1

90d 1

Best Calls

LLY long +1.4%

Worst Calls

No live losers yet

Most Mentioned

LLY ×1

Recent Calls

LLY long 14 hours ago

Win Rate 100% Long 1 Short 0

Win Rate

7d —

30d —

90d —

Average Return +1.4% Long Return +1.4% Short Return -

Average Return

7d —

30d —

90d —

Ticker

Side

Mentions

Opened

Entry

P&L

Thesis

Theme

Source

LLY Eli Lill... Eli Lilly and Company

Long

Jun 03

$1068.00

+1.4%

Oncology pipeline underappreciated, eight new medicines coming.

Lilly's oncology business is underappreciated by investors focused on GLP-1s, but it has line of sight to eight new cancer medicines or big label expansions, which he has seen clinical data for and believes will drive significant future growth, making Lilly a long-term compounder beyond just weight loss.

Healthcare

YOUTUBE

Showing 1 of 1 picks · sorted by mentions